相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD)
Wright W. Nichols et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)
The paradoxical in vivo activity of beta-lactams against metallo-beta-lactamase-producing Enterobacterales is not restricted to carbapenems
Kamilia Abdelraouf et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing Klebsiella pneumoniae (KPC-Kp) in Persistently Neutropenic Rabbits
Ruta Petraitiene et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam
Jianguo Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia
Shampa Das et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2020)
An amphipathic peptide with antibiotic activity against multidrug-resistant Gram-negative bacteria
Alysha G. Elliott et al.
NATURE COMMUNICATIONS (2020)
Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups
Jianguo Li et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2019)
Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia
Shampa Das et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Avibactam Sensitizes Carbapenem-Resistant NDM-1-Producing Klebsiella pneumoniae to Innate Immune Clearance
Erlinda R. Ulloa et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA-Specified End Points
Aatoni Torres et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
A model-based analysis of pharmacokinetic-pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa
S. K. B. Sy et al.
CLINICAL MICROBIOLOGY AND INFECTION (2019)
Efficacy of ceftazidime-avibactam in a rat intra-abdominal abscess model against a ceftazidime- and meropenem-resistant isolate of Klebsiella pneumoniae carrying blaKPC-2
Taryn Sleger et al.
JOURNAL OF CHEMOTHERAPY (2018)
Avibactam Pharmacokinetic/Pharmacodynamic Targets
Wright W. Nichols et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
A mathematical model-based analysis of the time-kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa
Sherwin K. B. Sy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
Antoni Torres et al.
LANCET INFECTIOUS DISEASES (2018)
Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa
Wright W. Nichols et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae
Wenxia Zhang et al.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2018)
In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products
Carlos A. Rodriguez et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia
Xinyu Qin et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis
Timothy J. Bensman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vitro Discordance with In Vivo Activity: Humanized Exposures of Ceftazidime-Avibactam, Aztreonam, and Tigecycline Alone and in Combination against New Delhi Metallo-β-Lactamase-Producing Klebsiella pneumoniae in a Murine Lung Infection Model
M. L. Monogue et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Establishment of Experimental Murine Peritonitis Model with Hog Gastric Mucin for CarbapenemResistant Gram- Negative Bacteria
Jung Yeon Park et al.
INFECTION AND CHEMOTHERAPY (2017)
Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection
Johanna Berkhout et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh Model
M. J. Melchers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients
John S. Bradley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
Florian M. Wagenlehner et al.
CLINICAL INFECTIOUS DISEASES (2016)
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
John E. Mazuski et al.
CLINICAL INFECTIOUS DISEASES (2016)
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
Yehuda Carmeli et al.
LANCET INFECTIOUS DISEASES (2016)
The postantibiotic effect and post--lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria
C. M. Pillar et al.
LETTERS IN APPLIED MICROBIOLOGY (2016)
Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs
Anders N. Kristoffersson et al.
PHARMACEUTICAL RESEARCH (2016)
Pharmacokinetics and Penetration of Ceftazidime and Avibactam into Epithelial Lining Fluid in Thigh- and Lung-Infected Mice
Johanna Berkhout et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
In Vitro Antibacterial Activity of the Ceftazidime-Avibactam Combination against Enterobacteriaceae, Including Strains with Well-Characterized β-Lactamases
Premavathy Levasseur et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery
Tjerk Bueters et al.
FUTURE MEDICINAL CHEMISTRY (2015)
Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam
Renu Singh et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Pharmacodynamics of Imipenem in Combination with β-Lactamase Inhibitor MK7655 in a Murine Thigh Model
Eleftheria Mavridou et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
In Vitro Activity of Ceftazidime-Avibactam Combination in In Vitro Checkerboard Assays
Johanna Berkhout et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
β-Lactamase inhibition by avibactam in Mycobacterium abscessus
Vincent Dubee et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Efficacies of Ceftazidime-Avibactam and Ceftazidime against Pseudomonas aeruginosa in a Murine Lung Infection Model
Seth T. Housman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Clinical Pharmacodynamics of Antipseudomonal Cephalosporins in Patients with Ventilator-Associated Pneumonia
Shawn H. MacVane et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
In Vivo Efficacy of Humanized Exposures of Ceftazidime-Avibactam in Comparison with Ceftazidime against Contemporary Enterobacteriaceae Isolates
Shawn H. MacVane et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Efficacy of a Ceftazidime-Avibactam Combination in a Murine Model of Septicemia Caused by Enterobacteriaceae Species Producing AmpC or Extended-Spectrum β-Lactamases
Premavathy Levasseur et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Bactericidal Activity, Absence of Serum Effect, and Time-Kill Kinetics of Ceftazidime-Avibactam against β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa
Tiffany R. Keepers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model
Ken Coleman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Background and Rationale for Revised Clinical and Laboratory Standards Institute Interpretive Criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam
Michael N. Dudley et al.
CLINICAL INFECTIOUS DISEASES (2013)
Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia
Anouk E. Muller et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial
Christopher Lucasti et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs
Elisabet I. Nielsen et al.
PHARMACOLOGICAL REVIEWS (2013)
Pharmacodynamics of β-Lactamase Inhibition by NXL104 in Combination with Ceftaroline: Examining Organisms with Multiple Types of β-Lactamases
Arnold Louie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Comparative In Vitro and In Vivo Efficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa
Jared L. Crandon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for β-Lactamase Inhibitors
Pratik Bhagunde et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
Jose A. Vazquez et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Evaluation of Ceftazidime and NXL104 in Two Murine Models of Infection Due to KPC-Producing Klebsiella pneumoniae
Andrea Endimiani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
Ken Coleman
CURRENT OPINION IN MICROBIOLOGY (2011)
Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients
Jason A. Roberts et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation
Christopher R. Frei et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo
Johan W. Mouton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Setting and revising antibacterial susceptibility breakpoints
John Turnidge et al.
CLINICAL MICROBIOLOGY REVIEWS (2007)
Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment
C. Andrew DeRyke et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2007)
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore
Paul G. Ambrose et al.
CLINICAL INFECTIOUS DISEASES (2007)
Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection
Irma A. J. M. Bakker-Woudenberg et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Making the most of surveillance studies: summary of the OPTAMA Program
JL Kuti et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2005)
Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations
D Andes et al.
CLINICAL MICROBIOLOGY AND INFECTION (2005)
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update
JW Mouton et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid
WA Craig
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2003)
Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases:: Report from the ARREST program
PG Ambrose et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam
MK Kim et al.
PHARMACOTHERAPY (2002)
Animal model pharmacokinetics and pharmacodynamics: a critical review
D Andes et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2002)
分享论文
